Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05645406 · ClinicalTrials.gov registry record · Early Phase 1
Estrogen Hormone Products
A Early Phase 1 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT05645406: Completed Early Phase 1 study, sponsored by University of Maryland, Baltimore.
NCT05645406 is a Early Phase 1 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 8 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05645406, a Early Phase 1 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose is to determine if the two estradiol products can deliver similar amounts of estradiol after single and multiple dosing.
Primary Outcome
serum concentrations
Interventions
- DRUG Divigel 0.1% Topical Gel
- DRUG Compounded estradiol product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2024-05-14 |
| Est. Completion | 2025-06-15 |
| Phase | Early Phase 1 |
What the finished NCT05645406 record still lists
NCT05645406 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Divigel 0.1% Topical Gel is the first listed.
NCT05645406 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05645406 about?
NCT05645406 is a clinical study titled "Estrogen Hormone Products". The purpose is to determine if the two estradiol products can deliver similar amounts of estradiol after single and multiple dosing.
What is the current status of trial NCT05645406?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2024-05-14. Estimated completion is 2025-06-15.
What interventions are being tested in trial NCT05645406?
The interventions under investigation include: Divigel 0.1% Topical Gel (DRUG), Compounded estradiol product (DRUG).
Who is sponsoring clinical trial NCT05645406?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05645406's enrollment target sits among peer trials
8 1783rd of 2000 higher than 176 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI